PULMATRIX, INC. Deferred Tax Liabilities, Gross
PULMATRIX, INC. (PULM) had Deferred Tax Liabilities, Gross of $2.82 million as of 2023-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2025-03-21
- 2023-12-31: Deferred Tax Liabilities, Gross $2.82M.
- 2022-12-31: Deferred Tax Liabilities, Gross $194.00K.
- 2021-12-31: Deferred Tax Liabilities, Gross $572.00K.
- 2020-12-31: Deferred Tax Liabilities, Gross $407.00K.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2023-12-31 | $2.82M 10-K · filed 2025-03-21 |
| 2022-12-31 | $194.00K 10-K · filed 2024-03-28 |
| 2021-12-31 | $572.00K 10-K · filed 2023-03-30 |
| 2020-12-31 | $407.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |